The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion
therapy has contributed to the understanding of B cells as major players in several …

The anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-
cell malignancies. This unprecedented success has not only substantially changed the …

Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …

B-cells play a major role in the immunopathogenesis of autoimmune diseases. Not only do
they produce autoantibodies, but they regulate other cell types, secrete cytokines, and …

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have
revolutionised the treatment of B cell hematological malignancies and have become a …

Rituximab, ocrelizumab, ofatumumab and ublituximab are disease modifying therapies
(DMT) currently used in the treatment of multiple sclerosis (MS) or are in advanced stages of …

The immune system plays a significant role in multiple sclerosis. While MS was historically
thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells …

Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …

Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has
been largely underestimated, and the disease was considered a T-cell-mediated disorder …

Background B cells can contribute to immune-mediated disorders. Targeting CD20 has
proved to be efficacious in several B cell-mediated immunopathologies, as illustrated by the …